Qiming Wang
CURRICULUM VITAE
NAME Qiming Wang
DATE OF BIRTH June 10, 1973
SEX Male
CITIZENSHIP P. R. China
TITLE Professor of Oncology
Vice Director
Department of Internal Medicine
The Affiliated Cancer Hospital of Zhengzhou University, China, P.R.C.
ADDRESS No.127 Doming Road, Zhengzhou, Henan, P.R.C.
TELEPHONE +86-13783590691
E-MAIL wangqiming@csco.org.cn
EDUCATION BACKGOUND:
Degree-Granting Education
Sept.2007-July.2010 Ph.D., Zhengzhou University, Zhengzhou, Henan, P.R.C.
Sept.2000-July.2003 Master of medicine, Zhengzhou University, Zhengzhou, Henan, P.R.C.
Sept.1991-July.1994 Medical degree of Clinic medicine, Henan Medical University, Zhengzhou, Henan, P.R.C
.
Postgraduate Training
Postdoctoral Fellow, Department of Epidemiology, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
WORK EXPERIENCE:
2013-present Vice Director, Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, P.R., China
2012-present Professor, Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, P.R., China
2010-2012 Associate Professor, Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, P.R., China
2005-2010 Instructor, Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, P.R., China
2003-2005 Resident, Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, P.R., China.
1994-2000 Resident, Department of Internal Medicine e, Kaifeng First People’s Hospital, Kaifeng, Henan, P.R., China
RESEARCH EXPERIENCE:
As a principal investigator, I have conducted the following funded research:
1. The screening and functional study of lung cancer stem cell marker genes SNPs of micro-RNA binding site (2012), funded by The National Natural Science Foundation of China (NSFC, No. 81272600)
2. The screening study of serum micro-RNA of lung cancer, Henan Provincial Special Funds for Health and Technological Innovative Talents (No. 2011020155), funded by the Health Department of Henan Province.
3. The screening and identifying study of functional micro-RNA of lung cancer, Henan Provincial Research Program of Application Foundation and Advanced Technology (No. 112300410033), funded by the Science and Technology Department of Henan Province.
HONORS AND AWARDS
1. Travel Awards of the 40th Annual Meeting of Korean Cancer Association (KCA), 2014
2. Travel Awards of the Annual Meeting of 51st Japan Society of Clinical Oncology (JSCO), 2013
3. Innovation talents of health science and technology, the Health Department of Henan Province, China, 2013
Publications:
1. Shen R, Liu H, Wen J, Liu Z, Wang LE, Wang Q, Tan D, Ajani JA, Wei Q. Genetic polymorphisms in the microRNA binding-sites of the thymidylate synthase gene predict risk and survival in gastric cancer. Mol Carcinog. 2014 Apr 23. doi: 10.1002/mc.22160. [Epub ahead of print]
2. Wen J, Liu H, Wang Q, Liu Z, Li Y, Xiong H, Xu T, Li P, Wang LE, Gomez DR, Mohan R, Komaki R, Liao Z, Wei Q.Genetic variants of the LIN28B gene predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. Eur J Cancer. 2014 Apr 25. pii: S0959-8049(14)00251-2. doi: 10.1016/j.ejca.2014.03.008. [Epub ahead of print]
3. Wang Q, Liu H, Xiong H, Liu Z, Wang LE, Qian J, Muddasani R, Lu V, Tan D, Ajani JA, Wei Q. Polymorphisms in the microRNA binding-site in the stem cell marker gene CD133 modify susceptibility to and survival of gastric cancer. Mol Carcinog. 2013 Dec 2. doi: 10.1002/mc.22113. [Epub ahead of print]
4. Xiong H, Liao Z, Liu Z, Xu T, Wang Q, Liu H, Komaki R, Gomez D, Wang LE, Wei Q. ATM Polymorphisms Predict Severe Radiation Pneumonitis in Patients With Non-Small Cell Lung Cancer Treated With Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys. 2012 Nov 12. doi:pii: S0360-3016(12)03602-4. 10.1016/j.ijrobp.2012.09.024
5. Qian J, Qu HQ, Yang L, Yin M, Wang Q, Gu S, Wu Q, Zhao X, Wu W, Wu J, Tan X, Chen W, Wang H, Wang J, Fan W, Chen H, Han B, Lu D, Wei Q, Jin L. Association Between CASP8 and CASP10 Polymorphisms and Toxicity Outcomes With Platinum-Based Chemotherapy in Chinese Patients With Non-Small Cell Lung Cancer. Oncologist. 2012;17(12):1551-61. doi: 10.1634/theoncologist.2011-0419. Epub 2012 Jul 27.
6. Wang QM, Wang S, Wang HJ, Li P, Ma ZY. MicroRNAs: novel biomarkers for lung cancer diagnosis, prediction and treatment. Exp Biol Med (Maywood). 2012; 237(3):227-35.
7. Zhang T, Zhao D, Wang Q, Yu X, Cui Y, Guo L, Lu SH. MicroRNA-1322 Regulates ECRG2 Allele Specifically and acts as a potential Biomarker in Patients with Esophageal Squamous Cell Carcinoma. Mol Carcinog. 2012 Feb 7. doi: 10.1002/mc.21880. [Epub ahead of print].
8. Wang H, Zhang G, Li P, Yan X, Wang Q, Zhu H, Qi G, Fan Q, Ma Z. Differential efficacy of gefitinib across age groups in treatment of advanced lung adenocarcinoma. Pharmazie. 2012; 67(1):80-5.
9. Wang QM, Qi YJ, Jiang Q, Ma YF, Wang LD. Relevance of serum estradiol and estrogen receptor beta expression in high-incidence area for esophageal squamous cell carcinoma. Med Oncol. 2011; 28(1):188-93.
10. Wang QM, Yuan L, Qi YJ, Ma ZY, Wang LD. Estrogen analogues: promising target for prevention and treatment of esophageal squamous cell carcinoma in high risk areas. Med Sci Monit. 2010; 16(7):HY19-22.
11. Wang Q, Wang H, Li P, Zhu H, He C, Wei B, Ma J, Ma Z. Erlotinib-based Perioperative Adjuvant Therapy for A Case of Unresectable Stage IIIA(N2) Non-Small Cell Lung Cancer. AM J MED SCI, 2010; 340(4):321-5.
12. Zhang T, Wang Q, Zhao D, Cui Y, Cao B, Guo L, Lu SH.The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin Sci (Lond). 2011, 121(10):437-47. (co-first author) .
13. Zhang T, Zhao D, Wang Q, Yu X, Cui Y, Guo L, Lu SH. MicroRNA-1322 Regulates ECRG2 Allele Specifically and acts as a potential Biomarker in Patients with Esophageal Squamous Cell Carcinoma. Mol Carcinog. 2012 Feb 7. doi: 10.1002/mc.21880. [Epub ahead of print].
14. Yan X, Zhu H, Wang H, Wang Q, Li P, Ma Z. The role of adjuvant chemotherapy in operable non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2011 Mar;14(3):281-5. Chinese.
15. Li P, Wang Q, Wang H, Ma Z. Research progresses of albumin-bound paclitaxel in the treatment of non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2010 Jul;13(7):748-52. doi: 10.3779/j.issn.1009-3419.2010.07.16. Chinese.
16. Wang QM, He CY, Ma ZY, et al. Detection of P53, inducible nitric oxide synthase, and vascular endothelial growthfactor in human esophageal squamous cell carcinoma tissue. Journal of Zhengzhou University(Medical Science), 2008, 47(2)：199 -202
17. Wang QM, Ma ZY, Zhu H ,et al. Low dose density pacilitaxel chemotherapeutic regimens combined with total parenteral nutrition as second-line chemotherapy for the patients with advanced gastric cancer. Chinese Journal of Oncology. 2008，17(2):159-161
18. Wang QM，He X, Ma ZY,et al. The Relationship between Sex Hormones, Sex Hormone Receptors and Sex and Age Distribution for Esophageal Squamous Cell Carcinoma. Chinese General Practice. 2008,13(7A):1140-1142
19. Wang QM, Zhuang ZH, Li JX,et al. Roles of sex hormones and sex hormone receptors in carecinogenesis of esophageal squamous cell carcinoma from high-incidence area for esophageal cancer. Chinese Journal of Oncology.2008,17(7)：618-620
20. Wang QM, Sun C, An JY,et al. Comparative the expression of estrogen and progesterone receptor in esophageal squamous cell carcinoma between the young patients and the old patients from high-incidence area for esophageal cancer. Chinese Journal of Practice Medicine. 2008,9(13):1-3
21. Wang QM, Sun C, An JY,et al. Age distribution of esophageal squamous cell Carcinoma was associated with the expressed alterations of sex hormone receptors. Chinese Journal of Cancer Prevention and Treatment. 2008,17
22. Song ZB, Gao SS, Yi XN, Li YJ, Wang QM, Zhuang ZH, Wang LD. Expression of MUC1 in esophageal squamous-cell carcinoma and its relationship with prognosis of patients from Linzhou city, a high incidence area of northern China. World J Gastroenterol, 2003; 9(3):404-407.
Abstract
1. Wang QM. Functional Polymorphisms in Cancer Stem Cell Marker Gene CD133 Predict Local Recurrence and Distant Metastasis in Non-Small Cell Lung Cancer Patients Treated With Definitive Radiotherapy. May 2-4, 2014. The 11th international conference of the Asian Clinical Oncology Society (ACOS), Taipei, Taiwan
2. .Wang QM. Functional Polymorphisms in Cancer Stem Cell Marker Gene CD133 Predict Local Recurrence and Distant Metastasis in Non-Small Cell Lung Cancer Patients Treated With Definitive Radiotherapy. Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131. 26-29 March 2014. The European Lung Cancer Conference (ELCC) 2014, Geneva, Switzerland.
3. Wang QM. Functional Polymorphisms in Cancer Stem Cell Marker Gene CD133 Predict Local Recurrence and Distant Metastasis in Non-Small Cell Lung Cancer Patients Treated With Definitive Radiotherapy. 2013.10. Annual Meeting of 51st The Japan Society of Clinical Oncology (JSCO)，Kyoto, Japan
4. Wang QM. Polymorphisms in the microRNA binding-site in the stem cell marker gene CD133 modify susceptibility to and survival of gastric cancer. 2013.11. The 22nd Asia Pacific Cancer Conference (APCC), Tianjin, China
5. Wang QM. Polymorphisms in the microRNA binding-site in the stem cell marker gene CD133 modify susceptibility to and survival of gastric cancer. Chinese Society of Clinical Oncology (CSCO).Xiamen, China, 2013
6. Wang QM, Liu HL, Wang Li-E, Amos CI, Spitz MR, Wei QY. Functional polymorphisms in the stem-cell related pathway affect susceptibility to non-small cell lung cancer: a finding from Texas lung cancer genome-wide association study. The 103rd Annual Meeting of the American Association for Cancer Research (AACR), Chicago, IL, 2012.
7. Wang Qiming, Zhang Tengfei, Zhao Dan，Cui Yaling, Guo Liping, Fan Qingxia, Lu Shih-Hsin. High level of microRNA-31 in Serum as a potential biomarker for diagnosis and prognosis in patients with esophageal squamous cell carcinoma. Chinese Society of Clinical Oncology (CSCO). Beijing. 2010.
8. Wang QM, Qi YJ, Jiang Q, Ma YF, Wang LD. Relevance of serum estradiol and estrogen receptor beta expression from a high-incidence area for esophageal squamous cell carcinoma in China. Chinese Society of Clinical Oncology (CSCO). Shanghai. 2008.
9. Wang QM, Zhuang ZH, Li JX, He CY, Ma ZY, Wang LD. Alterations of ER in the process of esophageal carcinogenesis from high-incidence area for esophageal cancer. Chinese Conference on Medical Oncology (CCMO). Zhengzhou. 2008.
10. Li JX, Wang LD, Zheng S, Liu B, Guo RF, Wang QM, Fan ZM, Chen H, Zhuang ZH, An JY, Sun C, Gao SG, Li JL, Song ZB, He XW, Li YJ, Gao SS, Guo HQ, Xie DL, Yi XN, Ding ZH and Yang CS. Analysis on color endoscopic mass survey (iodine staining) and surgically resected esophageal specimen on the subjects at high-incidence area for esophageal cancer in Henan. The 94th Annual Meeting of the American Association for Cancer Research (AACR), Washington, D.C. 2003.
Journal Reviewer
Annals of Oncology
Cancer
Biochimie
Cancer Medicine
APMIS
Books and Chapters:
1. Esophagus Cancer. (Editor, Published by Henan Science and Technology Publishing House, 2003)
2. Cancer Targeted Therapy. (Associate Editor-in chief, Published by Science Publishing House, 2012)
3. miRNA and Cancer. (Associate Editor-in chief, Published by Science Publishing House, 2013)
Membership of Professional Society:
Member of Chinese Society of Clinical Oncology (CSCO), China
Member of Chinese Medical Association (CMA), China
Member of American Association of Cancer Research, USA